Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Diverse Biotech has finalized a strategic transaction with Enveric Biosciences, granting exclusive global rights to develop and commercialize five novel compounds targeting adverse side effects from cancer treatments. The deal includes an undisclosed upfront payment and future royalties on sales. Diverse Biotech utilizes a sophisticated drug discovery platform, leveraging cannabinoids to create new drug candidates that may offer enhanced efficacy and reduced side effects compared to current therapies. This collaboration aims to expedite the availability of these treatments for oncology patients.
Enveric Biosciences (NASDAQ: ENVB) announced that CEO David Johnson will speak at two virtual investor conferences in March 2021. The first is the M Vest and Maxim Group Emerging Growth Conference on March 18, 2021, and the second is the Benzinga Biotech Small Cap Conference on March 25, 2021, where he will present at 12:30 p.m. ET and participate in a panel discussion at 11:40 a.m. ET. The company focuses on developing cannabinoid medicines aimed at improving cancer patients' quality of life, addressing conditions like radiodermatitis and chemotherapy-induced neuropathy.
Enveric Biosciences (NASDAQ: ENVB) has acquired an exclusive, perpetual license from Diverse Biotech to develop cannabinoid medicines aimed at improving the quality of life for cancer patients. The agreement involves five new drug molecules, enhancing Enveric's pipeline with four dermatology-focused and one pain-focused compound. This partnership is expected to leverage Diverse Biotech's patented drug delivery platform to combine CBD with existing treatments, targeting side effects of cancer therapies. Enveric aims to address unmet medical needs and expand its intellectual property portfolio.
Enveric Biosciences (NASDAQ: ENVB) has announced a strategic development collaboration and exclusive supply agreement with PureForm Global, Inc. This partnership aims to develop cannabinoid medicines that alleviate treatment side effects for cancer patients. PureForm will be Enveric's exclusive supplier of synthetic, non-cannabis-based CBD, with plans targeting conditions like radiodermatitis and chemotherapy-induced neuropathy. The agreement ensures a consistent supply of high-quality CBD for clinical studies and emphasizes rigorous scientific research to enhance treatment options for patients.
Enveric Biosciences, Inc. (NASDAQ: ENVB) announced the completion of its registered direct offering on February 11, 2021, selling 3,007,026 shares at $4.27 each, raising approximately $12.84 million. After fees, the net proceeds are about $11.5 million, which will be used for working capital and corporate purposes. Investors received warrants for an additional 1,503,513 shares at $4.90 each. The offering was made under existing SEC registration statements.
Enveric Biosciences Inc. (NASDAQ: ENVB) announced a registered direct offering of 3,007,026 shares at $4.27 each, totaling approximately $12.84 million in gross proceeds. The company will also issue unregistered warrants to acquire an additional 1,503,513 shares at $4.90 each. The offering, expected to close on February 11, 2021, aims to fund working capital and general corporate purposes. After the offering, Enveric will have 18,336,367 shares outstanding.
Enveric Biosciences (NASDAQ: ENVB) issued a shareholder letter highlighting corporate initiatives and strategic vision to enhance quality of life for cancer patients. The company recently secured $10 million in financing and aims to accelerate its pipeline focusing on supportive care therapies addressing severe side effects of cancer treatments. Enveric's leadership team comprises seasoned executives from top healthcare firms. The company plans to collaborate with leading oncology centers to advance its research in cancer treatment side effects like radiation dermatitis and CIPN, targeting clinical trials in 2021.
Enveric Biosciences (NASDAQ: ENVB) has closed a $10 million registered direct offering on January 14, 2021, selling 2,221,358 shares at a price of $4.5018 per share. The offering included unregistered warrants for 1,666,019 shares at $4.9519 per share, exercisable immediately for five years. After costs, net proceeds are approximately $9 million, which will be allocated for working capital and general corporate purposes. The offering was made under a Form S-3 registration statement previously filed with the SEC.
Enveric Biosciences Inc. (NASDAQ: ENVB) has announced a registered direct offering of 2,221,358 shares at $4.5018 per share, totaling approximately $10 million in gross proceeds. The company will also issue warrants for 1,666,019 shares at $4.9519 each. The offering is set to close on January 14, 2021, pending customary conditions. The funds will be used for general corporate purposes, potentially enhancing growth. Palladium Capital Group served as the financial advisor for this transaction.
Enveric Biosciences (NASDAQ: ENVB) has appointed Dr. Marcus Schabacker to its Board of Directors on January 5, 2021. Dr. Schabacker, possessing over 35 years of healthcare experience, is recognized for his work at ECRI Institute and Baxter Healthcare. His expertise aligns with Enveric's mission to develop cannabinoid medicines aimed at improving the quality of life for cancer patients, particularly focusing on treating side effects from cancer therapies. The company aims to leverage Dr. Schabacker's insights to enhance its research and development efforts.